In this study, the role of particle encapsulation on the tumor-suppressive capability and side effects of the IL-1 was investigated. The study is well-designed, with results that support the claims of the manuscript. However, I the have following comments to be addressed before the publication of the manuscript:

Major Comments:
1. Is it possible to do a survival study in this animal model to have another way to confirm the long-term efficacy and tumor-suppressive capability of the platform? The results showing the reduced side effects via MP encapsulation and sustained release of the drug are satisfactory and compelling. However, currently, the only approach to confirm the efficacy of particles is the characterization of tumor-infiltrating immune cells and the tumor volume. I believe adding the survival results can strengthen the manuscript and confirm the therapeutic efficacy of particles.

Minor Comments:
1. The expanded form of CPTEG-CPH needs to be added to the text the first time it is mentioned in the manuscript (the first paragraph of the discussion).
2. In the second paragraph of the discussion, the word “CPTEG:CPH IL-1A-MPs” is mentioned, while it is earlier indicated that these particles were nanoparticles. Thus, the wording needs to be changed to resolve the inconsistency.

My previous comments were addressed in the revised version.